+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Bipolar Disorder Therapeutic Market 2019-2023 - Product Image

Global Bipolar Disorder Therapeutic Market 2019-2023

  • ID: 4659393
  • Report
  • Region: Global
  • 104 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • MORE
About Bipolar Disorder

Bipolar disorder is also known as manic depression that causes extreme shifts in mood, energy, and activity levels. Elevated mood swings are called mania or hypomania, which differs based on the severity and presence of psychosis. Bipolar disorder is a long-lasting condition that can be categorized into bipolar I, bipolar II, and cyclothymia. This condition can be managed with a regular treatment. Insomnia, weight gain or loss, behavioral changes, and psychological imbalances are some of the symptoms witnessed in individuals with bipolar disorder.

The analysts forecast the Global Bipolar Disorder Therapeutics Market to grow at a CAGR of 2.38% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the bipolar disorder therapeutics market. To calculate the market size, the report considers the revenue generated from the application of bipolar disorder therapeutics across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, bipolar disorder therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
  • Allergan
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
Market drivers
  • Growing prevalence of mental health disorders (MHDs) across the globe.
  • For a full, detailed list, view the full report
Market challenges
  • Lack of adequate diagnosis process
  • For a full, detailed list, view the full report
Market trends
  • Growing number of strategic alliances
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2023 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antipsychotics - Market size and forecast 2018-2023
  • Anticonvulsants - Market size and forecast 2018-2023
  • Traditional mood stabilizers - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
PART 15: EXPLORE THE AUTHOR

List of Exhibits
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global cns therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Market size and forecast 2018-2023 ($ mn)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 21: Anticonvulsants - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Anticonvulsants - Year-over-year growth 2019-2023 (%)
Exhibit 23: Traditional mood stabilizers - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Traditional mood stabilizers - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: ALLERGAN - Vendor overview
Exhibit 46: ALLERGAN - Business segments
Exhibit 47: ALLERGAN - Organizational developments
Exhibit 48: ALLERGAN - Geographic focus
Exhibit 49: ALLERGAN - Segment focus
Exhibit 50: ALLERGAN - Key offerings
Exhibit 51: AstraZeneca - Vendor overview
Exhibit 52: AstraZeneca - Business segments
Exhibit 53: AstraZeneca - Organizational developments
Exhibit 54: AstraZeneca - Geographic focus
Exhibit 55: AstraZeneca - Segment focus
Exhibit 56: AstraZeneca - Key offerings
Exhibit 57: Eli Lilly - Vendor overview
Exhibit 58: Eli Lilly - Business segments
Exhibit 59: Eli Lilly - Organizational developments
Exhibit 60: Eli Lilly - Geographic focus
Exhibit 61: Eli Lilly - Segment focus
Exhibit 62: Eli Lilly - Key offerings
Exhibit 63: GlaxoSmithKline - Vendor overview
Exhibit 64: GlaxoSmithKline - Business segments
Exhibit 65: GlaxoSmithKline - Organizational developments
Exhibit 66: GlaxoSmithKline - Geographic focus
Exhibit 67: GlaxoSmithKline - Segment focus
Exhibit 68: GlaxoSmithKline - Key offerings
Exhibit 69: Johnson & Johnson - Vendor overview
Exhibit 70: Johnson & Johnson - Business segments
Exhibit 71: Johnson & Johnson - Organizational developments
Exhibit 72: Johnson & Johnson - Geographic focus
Exhibit 73: Johnson & Johnson - Segment focus
Exhibit 74: Johnson & Johnson - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • MORE
New Report Released: - Global Bipolar Disorder Therapeutics Market 2019-2023

The author of the report recognizes the following companies as the key players in the global bipolar disorder therapeutics market: Allergan, AstraZeneca, Eli Lilly, GlaxoSmithKline, and Johnson & Johnson.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the growing number of strategic alliances between vendors. Most of the vendors are focused on entering into strategic alliances to develop the most effective treatment for bipolar treatment and expand their product portfolio.”

According to the report, one driver influencing this market is the growing prevalence of mental health disorders (MHDs) across the globe. The rising incidences of these MHDs is resulting in a great need for the development of the most effective treatment for bipolar disorder.

Further, the report states that one challenge affecting this market is the lack of adequate diagnosis process. The lack of a proper technical diagnostic process is a key challenge in the global bipolar disorder therapeutics market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Allergan
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4659393
Adroll
adroll